Skip to content
    AQST
    Earnings call· Jun 2026(Q2 FY26)

    Aquestive Therapeutics Q2 FY26 earnings call AQST

    Aug 12, 2026 Source

    Executive summary

    Aquestive Q2 FY26 — Anaphylm Resubmission On Track, Strong Clinical Data

    Aquestive Therapeutics is on track to resubmit its Anaphylm NDA in Q3 2026, bolstered by positive human factors and PK study data addressing prior FDA concerns. The company is preparing for a potential launch with a focused allergist strategy and believes Anaphylm offers significant clinical differentiation in a growing epinephrine market. Strategic partnering for Libervant and ex-U.S. Anaphylm, alongside the advancement of AQST-108, aims to diversify future growth.

    Highlights

    5
    • Anaphylm NDA resubmission on track for Q3 2026, less than 8 months after CRL.

    • Human factors study showed significant reduction in packaging difficulty (from 26 to 1 participant) and film tearing (from 6 to 0).

    • PK study showed no statistical difference between clinician-administered and self-administered Anaphylm.

    • Off-label administration (top of tongue) showed rapid and meaningful pharmacodynamic responses comparable to manual IM epinephrine.

    • Total revenues increased 38% YoY to $13.8 million in Q2 2026 and 51% YoY to $28.3 million for H1 2026.

    Concerns

    1
    • Net loss for Q2 2026 was $22.9 million, compared to $13.5 million in Q2 2025, primarily due to a one-time $11.7 million loss on extinguishment of debt.

    Guidance & targets

    7
    CategoryTargetConfidence
    Anaphylm NDA Resubmission
    Before end of Q3 2026
    high materiality
    High
    Anaphylm FDA Review Timeline
    6 months
    high materiality
    Medium
    Anaphylm Launch Funding (RTW)
    $75 million
    high materiality
    High
    Anaphylm Launch Funding (Oaktree)
    $20 million
    high materiality
    High
    Full-year 2026 Total Revenue
    $46 million to $50 million
    high materiality
    High
    Full-year 2026 Non-GAAP Adjusted EBITDA Loss
    $35 million to $30 million
    high materiality
    High
    Anaphylm Ex-U.S. Filings
    Canada, Europe, U.K.
    medium materiality
    High

    Segment performance

    2
    SegmentRevenueYoYQoQMargin
    Manufacture and Supply Revenue
    Primarily driven by increases in Suboxone revenues, partially offset by lower Ondif revenues.
    Q2 FY25 Revenue: $9.6 millionH1 FY26 Revenue: $20.7 millionH1 FY25 Revenue: $16.8 million
    $11.9 million
    License and Royalty Revenue
    Primarily due to royalty revenue from Zevra.
    Q2 FY25 Revenue: $0.8 millionH1 FY26 Revenue: $6.7 millionH1 FY25 Revenue: $1.6 million
    $1.3 million

    Operational metrics

    25
    Total Revenue Increase
    51%YoY
    H1 FY26

    Increase in total revenues for the 6 months ended June 30, 2026, compared to the same period in 2025.

    SG&A Expenses - Lower Commercial Spending
    $2.6 millionlower YoY
    Q2 FY26

    Lower commercial spending contributed to the change in SG&A expenses.

    SG&A Expenses - Higher Legal Fees
    $2.1 millionhigher YoY
    Q2 FY26

    Higher legal fees contributed to the change in SG&A expenses.

    SG&A Expenses - Higher Severance Costs
    $1.4 millionhigher YoY
    Q2 FY26

    Higher severance costs contributed to the change in SG&A expenses.

    SG&A Expenses - Higher Personnel Costs
    $0.9 millionhigher YoY
    Q2 FY26

    Higher personnel costs contributed to the change in SG&A expenses.

    SG&A Expenses - Higher Share-Based Compensation
    $0.3 millionhigher YoY
    Q2 FY26

    Higher share-based compensation expenses contributed to the change in SG&A expenses.

    SG&A Expenses - Lower Regulatory and Licensing Fees
    $1.2 millionlower YoY
    Q2 FY26

    Lower regulatory and licensing fees contributed to the change in SG&A expenses.

    Loss on Extinguishment of Debt
    $11.7 million
    Q2 FY26

    One-time loss recognized from the refinancing of 13.5% notes.

    Net Loss Excluding Loss on Extinguishment of Debt
    $11.2 million
    Q2 FY26

    Adjusted net loss for the second quarter of 2026.

    Net Loss Excluding Loss on Extinguishment of Debt
    $19.2 million
    H1 FY26

    Adjusted net loss for the 6 months ended June 30, 2026.

    Non-GAAP Adjusted EBITDA Loss
    $5.2 millionvs $9.3 million loss in Q2 FY25
    Q2 FY26

    Improved non-GAAP adjusted EBITDA performance.

    Non-GAAP Adjusted EBITDA Loss
    $7 millionvs $27 million loss in H1 FY25
    H1 FY26

    Improved non-GAAP adjusted EBITDA performance for the first half of the year.

    Cash and Cash Equivalents
    $98.5 million
    Q2 FY26

    Balance sheet cash position at the end of the second quarter.

    Epinephrine Rescue Market Growth Rate
    6%YoY
    Annual

    The epinephrine rescue market has been growing consistently, including year-to-date 2026.

    Epinephrine Branded Products Market Opportunity
    $1 billion
    Annual

    Estimated market opportunity for epinephrine branded products, with potential to double over time.

    Anaphylm Human Factors Study - Difficulty Opening
    1vs 26 in previous study
    Most recent study

    Number of participants who showed difficulty opening the updated Anaphylm packaging, a significant reduction.

    Anaphylm Human Factors Study - Film Tearing
    0vs 6 in previous study
    Most recent study

    Number of participants who tore the updated Anaphylm film, indicating improved packaging.

    Anaphylm Human Factors Study - Misplaced Dose
    2vs 20 in previous study
    Most recent study

    Number of participants who misplaced the dose during administration with updated instructions, a significant reduction.

    SG&A Expenses - Lower Commercial Spending
    $4.5 millionlower YoY
    H1 FY26

    Lower commercial spending for the 6 months ended June 30, 2026, compared to the same period in 2025.

    Anaphylm PDUFA Fee
    $4.3 million
    Prior year period

    One-time PDUFA fee for Anaphylm incurred in the prior year period, impacting H1 SG&A comparison.

    SG&A Expenses - Lower Legal Fees
    $1.3 millionlower YoY
    H1 FY26

    Lower legal fees for the 6 months ended June 30, 2026, compared to the same period in 2025.

    SG&A Expenses - Lower Regulatory and Licensing Fees
    $1.9 millionlower YoY
    H1 FY26

    Lower regulatory and licensing fees for the 6 months ended June 30, 2026, compared to the same period in 2025.

    SG&A Expenses - Higher Severance Costs
    $2 millionhigher YoY
    H1 FY26

    Higher severance costs for the 6 months ended June 30, 2026, compared to the same period in 2025.

    SG&A Expenses - Higher Personnel Costs
    $1.4 millionhigher YoY
    H1 FY26

    Higher personnel costs for the 6 months ended June 30, 2026, compared to the same period in 2025.

    SG&A Expenses - Higher Share-Based Compensation
    $1.8 millionhigher YoY
    H1 FY26

    Higher share-based compensation expenses for the 6 months ended June 30, 2026, compared to the same period in 2025.

    Industry KPIs

    6
    MetricValueDetails
    Prescription volume6%%
    EPS revenue guidanceFY26 Total Revenue: $46M-$50M; FY26 Non-GAAP Adjusted EBITDA Loss: $35M-$30MUSD
    Pipeline clinical milestonesAnaphylm NDA resubmission on track for Q3 2026
    Regulatory approvals filingsAnaphylm NDA resubmission
    Clinical trial efficacy safety dataPositive human factors and PK study results for Anaphylm
    Business development capacity deal appetite$75M from RTW, $20M from OaktreeUSD

    Deals & partnerships

    5
    OaktreeRefinancing of debt facility$150 million

    Established a new $150 million debt facility with Oaktree.

    IndiviorLongstanding relationship for Suboxone manufacturing20 years

    Continued manufacturing and supply relationship for Suboxone sublingual film.

    Cosette PharmaceuticalsCommercialization of Sympazan

    Cosette Pharmaceuticals is commercializing Sympazan, with Aquestive viewing them as a good home for the product.

    UndisclosedPartnering for Libervant in the U.S.

    Engaging in active partnering processes for Libervant in the U.S.

    UndisclosedPartnering for Anaphylm outside of the U.S.

    Engaging in active partnering processes for Anaphylm outside of the U.S.

    Risks & headwinds

    3
    FDA Review Timeline UncertaintyPost Q3 2026 Anaphylm resubmission

    Standard 6-month review, but potential for faster review is uncertain.

    Mitigation: Engaging with FDA to advocate for expedited review; commercial team preparing for variable timelines.

    Payer Adoption of Branded EpinephrinePost Anaphylm approval and launch

    Epinephrine rescue market largely generic.

    Mitigation: Highlighting Anaphylm's clinical differentiation (Tmax, blood pressure changes) and ease of use/carry to payers; building active pricing strategy.

    Patient Switch from Existing Auto-injectorsPost Anaphylm approval and launch

    Competitor noted patients tend to refill rather than return to prescriber.

    Mitigation: Patients typically see allergists annually for prescriptions; Aquestive plans a balanced and integrated approach across multiple channels to drive conversations with patients and allergists, leveraging Anaphylm's compelling switch story and clinical differentiation.

    What to watch in Q3 FY26

    4

    Anaphylm NDA Resubmission

    Q3 FY26
    CurrentOn track for Q3 2026
    TargetCompletion of resubmission

    Why it matters

    Successful resubmission is a critical step towards potential FDA approval and commercialization.

    I am excited to share today that not only have we completed the necessary studies for Anaphylm resubmission, but that we remain on track to resubmit before the end of this quarter.

    Q&A highlights

    6

    How do the recent PK and human factors study data increase conviction in the resubmission, and what are the updated thoughts on a potentially shorter FDA review timeframe?

    Management believes the new data thoroughly addresses FDA concerns, especially regarding packaging and administration. The standard review time is 6 months, but they will advocate for an expedited review given the thin package and prior FDA clinical team buy-in.

    We will be pressing them in a supportive way, not in an aggressive way, that this is an opportunity to move faster. So whether they take that opportunity or not is up to them, and the standard time would be 6 months.

    asked by Roanna Clarissa Ruiz · answered by Daniel Barber

    2 min read5 chapters

    Detailed Narrative

    01

    Anaphylm Resubmission and Clinical Data

    Aquestive is on track to resubmit its Anaphylm NDA to the FDA in Q3 2026, following a complete response letter earlier in the year. The resubmission includes results from a human factors validation study, which showed a significant reduction in packaging difficulty and film tearing after updates. A pharmacokinetic (PK) study demonstrated no statistical difference between clinician-administered and self-administered drug product, and even with purposeful misplacement (top of tongue), rapid and meaningful pharmacodynamic responses were observed, comparable to manual IM epinephrine.

    02

    Anaphylm Market Opportunity and Commercial Strategy

    The company believes the epinephrine rescue market, estimated at $1 billion to potentially $2 billion annually, presents a compelling opportunity for Anaphylm. The market has grown annually by approximately 6% and is dominated by outdated technology. Aquestive plans an allergist-focused launch strategy to efficiently convert prescriptions, emphasizing Anaphylm's clinical differentiation, ease of use, and portability. Payer coverage is anticipated to be driven by the product's clinical benefits beyond just being a 'no-needle' solution.

    03

    AQST-108 Atopic Dermatitis Program

    Aquestive is advancing AQST-108 for atopic dermatitis, leveraging a localized topical epinephrine application. Preclinical and human trials have shown TSLP, CCL3, and CCL4 suppression, and NF-KB modulation, which are key in alleviating itch associated with atopic dermatitis. The company believes this approach could offer a meaningful treatment, potentially with less frequent dosing than daily, positioning it against both low-cost generics and higher-priced biologics. Further updates are expected after the Anaphylm resubmission.

    04

    Partnering and Base Business Activities

    The company is actively pursuing partnering opportunities for Libervant in the U.S. and Anaphylm outside of the U.S. The base business, including Suboxone manufacturing, continues to generate consistent cash flow. Management believes the proposed Indivior-Supernus merger will not have a near-term impact on its base business, given the ongoing importance of Suboxone. The refinancing with Oaktree provides a new $150 million debt facility, lowering capital costs and extending the interest-only period.

    05

    Financial Performance and Capital Allocation

    Aquestive reported a 38% increase in total revenues for Q2 2026 and a 51% increase for the first six months of 2026, driven by manufacturing and supply, and license and royalty revenues. Non-GAAP adjusted EBITDA loss improved significantly year-over-year. The company ended Q2 with $98.5 million in cash and cash equivalents and expects additional launch funding of $75 million from RTW and $20 million from Oaktree upon Anaphylm FDA approval. Capital allocation remains disciplined, focusing on Anaphylm resubmission, launch preparations, and AQST-108 advancement.

    AI-generated summary of the company’s earnings call. Not investment advice.